UT MD Anderson and P-Cure collaborate to advance first compact upright dual-modality proton and helium ion therapy platform
The University of Texas MD Anderson Cancer Center and P-Cure Ltd. today announced a strategic alliance to advance the development and clinical validation of a next-generation particle therapy platform designed to deliver both proton and helium ion therapy from a single compact upright treatment system.
The collaboration combines UT MD Anderson's expertise in radiation oncology, particle therapy and translational cancer research...
UT MD Anderson announces historic expansion of cancer care facilities
The University of Texas MD Anderson Cancer Center today announced the historic expansion of its Texas Medical Center (TMC) campus through two...
Susan Bullman receives TAMEST Mary Beth Maddox Award for breakthrough tumor microbiome research
Susan Bullman, Ph.D., associate professor of Immunology and Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer...
Allison Institute convenes leading scientists and clinicians for fourth annual scientific symposium on frontiers of immunotherapy
Annual meeting focused on immune set points andthe regulatory mechanisms shaping the next generation of cancer immunotherapies
Symposium featured a panel discussion with five Nobel laureates moderated by TIME Senior Health Correspondent Alice Park
The James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center hosted its fourth annual scientific symposium, “Immune Set Points: Stress, Wellness and System Control,...
Newly discovered pathway fuels production of cancer-driving proteins
Researchers identified a previously unknown mechanism that helps cancer cells produce cancer-promoting proteins, including KRAS
Blocking a specific...
ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer
Phase 3 trial finds that next-generation KRAS G12C inhibitor divarasib significantly reduced risk of cancer progressing and death...
ESMO 2026: UT MD Anderson highlights innovative approaches to monitor, prevent and treat cancer
ABSTRACTS: 3438O, 4244RO, 540RO, 2490P
Researchers at The University of Texas MD Anderson Cancer Center presented new findings at the...
ESMO 2026: Immunotherapy combination extends survival in advanced endometrial cancer
Patients receiving durvalumab plus olaparib lived almost one year longer than patients treated with chemotherapy alone
Study...
UT MD Anderson welcomes eight new members to Board of Visitors
The University of Texas MD Anderson Cancer Center is pleased to announce eight new members to its Board of Visitors (BOV), the institution...
UT MD Anderson names 2026 winners of The Brown Foundation Award for Excellence in Oncology Nursing
The University of Texas MD Anderson Cancer Center yesterday awarded Lakeisha Keller-Davis, RN, MSN, CMSRN, and Ellen C. Mullen, Ph.D., APRN-BC...